- Supported exchanges /
- F /
- 7AY1.F
ACTINIUM PHARMAC. DL-001 (7AY1 F) stock market data APIs
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.
ACTINIUM PHARMAC. DL-001 Financial Data Overview
1.637 | |
1.637 | |
- | |
1.637 | |
1.637 | |
1.41-9.8 | |
51 902 K | |
31 154 K | |
81 000 | |
0.143 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
ACTINIUM PHARMAC. DL-001 Fundamental Data is available in our Financial Data APIs
- Net Revenue 81 000
- EBITDA -46 485 000
- Earnings Per Share -1.4
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get ACTINIUM PHARMAC. DL-001 Earnings via APIs
- Latest Release 2024-10-31
- EPS/Forecast NaN
Get ACTINIUM PHARMAC. DL-001 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: